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Correspondence
In Brief Zhong et al. report that abnormal expression of ORP4L is essential for leukemia stem cell survival; it enables IP 3 generation by extracting and presenting PIP 2 from the plasma membrane to PLCb3 for hydrolysis. The compound LYZ-81, which blocks this process via targeting ORP4L, selectively eradicates leukemia stem cells.
INTRODUCTION
Leukemia stem cells (LSCs) are a rare subpopulation of abnormal hematopoietic stem cells that propagates leukemia (Elert, 2013; Lapidot et al., 1994) and is responsible for the high frequency of relapse that is characteristic of current leukemia therapies (Schepers et al., 2015) . Initially, LSCs were identified as having the CD34 + CD38 À phenotype, similar to normal hematopoietic stem cells (HSCs) (Bonnet and Dick, 1997) . Leukemia initiating and maintaining capacity has been described in other immunophenotypically defined acute myeloid leukemia (AML) subpopulations (Eppert et al., 2011) . However, immature CD34 + CD38 À cells remain the best-characterized and most potent population initiating leukemia in various xenograft mouse models and retransplantation experiments (Bonnet and Dick, 1997; Eppert et al., 2011; Ishikawa et al., 2007; Lechman et al., 2016; Reya et al., 2001; Saito et al., 2010) . LSCs share many properties, such as self-renewal, differentiation potential, and quiescent cell-cycle status, with HSCs (Clevers, 2011; Huntly and Gilliland, 2005) . The tendency to remain quiescent renders LSCs resistant to conventional chemotherapeutic agents and radiation, which predominantly target proliferating cells (Huntly and Gilliland, 2005; Tallman et al., 2005) . Hence, failure to eradicate quiescent LSCs may result in reinitiating the malignancy after a period of latency. It is therefore crucial to develop therapeutic approaches that target quiescent LSCs.
The second messenger inositol-1,4,5-trisphosphate (IP 3 ) is generated by the hydrolysis of phosphatidylinositol-4,5bisphosphate (PIP 2 ) located in the plasma membrane (PM) by phospholipase C (PLC) (Rhee et al., 1989) . When a ligand binds to a receptor coupled to a Gq heterotrimeric G protein, the a-subunit of Gq induces the activity of PLCb, resulting in the cleavage of PIP 2 into IP 3 and diacylglycerol (DAG) (Qin et al., 2011) . The binding of IP 3 to receptors in the endoplasmic reticulum (ER) results in Ca 2+ egress and mediates a range of cellular responses (Berridge et al., 2000) .
Oxysterol-binding protein (OSBP) and its relatives (ORPs) have emerged as mediators of the interorganelle transfer of cholesterol or phospholipids in exchange for phosphatidylinositol-4-phosphate (PI(4)P) (Mesmin et al., 2013; Tong et al., 2013; Yang, 2006) . OSBP mediates sterol and PI(4)P exchange between the ER and the Golgi (Mesmin et al., 2013) , while ORP5/8 exchange phosphatidylserine (PS) for PI(4)P at ER-PM junctions (Chung et al., 2015; Sohn et al., 2018) . An essential role of ORP5/8 as a transporter for PIP 2 rather than PI(4)P has recently been explored (Ghai et al., 2017) , and ORP2 acts as a selective transporter of cholesterol and PIP 2 at the PM (Wang et al., 2018) . Earlier studies suggested that ORP4L may be aberrantly induced in distinct malignant cell types (Charman et al., 2014; Fournier et al., 1999; Henriques Silva et al., 2003) . Our recent work showed that ORP4L is expressed in T cell acute lymphoblastic leukemia (T-ALL) cells but not normal T cells and is essential for cell survival (Zhong et al., 2016b) . ORP4L controls G protein-coupled IP 3 signaling in T-ALL cells and plays an obligatory role in efficient ATP production via oxidative phosphorylation. However, the mechanism through which ORP4L regulates PLCb3 catalysis is poorly understood. Given the critical role of ORPs in phosphoinositide metabolism and transport, understanding how ORP4L facilitates IP 3 generation by PLCb3 is a fundamental and clinically significant question.
In this study, we report that ORP4L executes an essential function in the survival of LSCs: it extracts PIP 2 from the PM and presents it to PLCb3 for hydrolysis, inaugurating the concept that a PIP 2 -presenting cofactor is required for PLC catalysis. Moreover, we explore a compound, LYZ-81, that blocks ORP4L function to eradicate leukemia.
RESULTS
ORP4L Is Selectively Expressed in LSCs, but Not HSCs, and Is Essential for the Survival of LSCs Our previous study showed that the abnormal expression of ORP4L is essential for T-ALL cell survival (Zhong et al., 2016b) . The crucial role of LSCs that propagate leukemia (Lapidot et al., 1994) prompted us to investigate the role of ORP4L in this cell type. LSCs from AML constitute the best-characterized LSC subpopulation (Schepers et al., 2015) . We isolated LSCs from the bone marrow of AML patients by using the CD34 + CD38 À markers and validated the stem cell status of the isolated cells (see Method Details). High levels of ORP4L mRNA and protein were detected in all CD34 + CD38 À -LSCs specimens, whereas they were absent in HSCs (Figures 1A and 1B) .
To investigate a putative role of ORP4L in the LSCs, we carried out knockdown experiments demonstrating that ORP4L depletion reduced the colony-forming capacity of the LSCs (Figure 1C) , accelerated the death of LSCs ( Figure 1D ), and significantly reduced the in vivo engraftment of LSCs in NOD/SCID mice ( Figure 1E ). To control for possible off-target effects, we carried out a number of RNA interference experiments by using another independent ORP4L small hairpin RNA (shRNA), with similar results (Figures S1A and S1B). The results suggested that ORP4L is expressed in LSCs and is required for the survival of these cells.
LYZ-81 Is a Specific Inhibitor of ORP4L
The role of ORP4L in LSCs survival prompted us to investigate the possibility of targeting ORP4L for leukemia therapy. OSW-1 is an anti-proliferative compound that targets ORP4L and OSBP (Burgett et al., 2011) . ORP4L shows a restricted tissue expression pattern, whereas OSBP is ubiquitous (Udagawa et al., 2014) . We hypothesized that the toxicity of OSW-1 toward normal cells may be due to its affinity for OSBP; thus, a compound sparing OSBP could be more selective toward cancer cells. To this end, we synthesized OSW-1 analogs, as described (Zheng et al., 2010) , and uncovered a compound called LYZ-81 ( Figure 2A ) that exhibited a drastically more pronounced difference in the half-maximal inhibitory concentration (IC 50 ) toward LSCs versus HSCs (IC 50 = 3.27 nM in LSCs versus IC 50 = 1.29 mM in HSCs) than OSW-1 ( Figures S2A and S2B ). Surface plasmon resonance (SPR) assays demonstrated that LYZ-81 binds ORP4L (K d = 1.05 ± 0.24 nM; Figure 2B ). Homology modeling and molecular docking studies suggested that LYZ-81 binds to ORP4L via hydrogen bonding, forming a stable complex through four residues-Met527, Arg594, Asn600, and Lys681-within the oxysterol-binding domain (ORD) of ORP4L ( Figure 2C ). To experimentally validate the in silico docking analysis, we constructed an ORP4L mutant, designated ORP4L M4 (Met527Gly, Arg594Gly, Asn600Gly, and Lys681Gly). SPR analyses demonstrated that ORP4L M4 shows a very low affinity for LYZ-81 ( Figure S2C ), indicating a key role of the four residues in the binding of the compound to ORP4L. This binding mode of LYZ-81 to ORP4L was further supported by experiments in which overexpression of wild-type ORP4L but not ORP4L M4 partly rescued LSCs from death induced by LYZ-81 ( Figure 2D ). LYZ-81 showed a dose-dependent cytotoxicity toward LSCs at 1-10 nM concentrations, while there was no effect on HSCs even at the highest dose (Figures 2E and 2F; Table S1 ), as evidenced by the induction of cell death and inhibition serials of colony formation. Together, the data indicate that LYZ-81 eradicates LSCs but not HSCs in vitro.
To address the specificity of LYZ-81 binding to ORP4L, we used SPR assays to determine the binding affinity of OSW-1 and LYZ-81 to ORP4L and OSBP. OSW-1 displays a similar, nanomole binding affinity for these two proteins (K d (ORP4L) = 0.85 ± 0.17 nM, K d (OSBP) = 1.49 ± 0.26 nM) (Figures S2D and S2E) . By contrast, LYZ-81 binds ORP4L with markedly greater affinity than OSBP (K d (ORP4L) = 1.05 ± 0.24 nM, K d (OSBP) = 5.9 ± 1.86 mM) ( Figures 2B and S2F) , revealing a strong preference of LYZ-81 for ORP4L. OSW-1 was shown to promote OSBP degradation via a proteasome-dependent pathway (Burgett et al., 2011) . To determine whether OSW-1 or LYZ-81 also causes a reduction in the amount of ORP4L, we assessed ORP4L protein levels in compound-treated LSCs by western blotting. Treatment with either compound did not affect ORP4L protein levels ( Figure S2G ). While OSW-1 induced a dramatic reduction of OSBP in LSCs, no such effect was seen in LYZ-81 treated cells ( Figure S2G ), adding evidence for the specificity of this compound for ORP4L. Overexpression of either ORP4L or OSBP protected LSCs against cell death induced by OSW-1. However, only ORP4L but not OSBP protected the cells against the cytotoxicity of LYZ-81 ( Figure S2H ). LYZ-81 executes cytotoxic activity toward LSCs via targeting ORP4L, while sparing OSBP.
To evaluate the cytotoxicity of OSW-1 and LYZ-81 in vivo, intravenously [i.v.] ) or LYZ-81 (5.8 mg/ kg/day, i.v.) (Tamura et al., 1997) were injected into mice for 7 weeks. Histological analysis revealed that LYZ-81 treatment did not alter the gross histology of spleen, bone marrow, heart, brain, kidney, or muscle of the animals ( Figure S2I ). However, the spleen and bone marrow of OSW-1 treated mice displayed abnormal cell morphology, smaller cell size, and narrowing of intercellular spaces ( Figure 2G ). These observations are consistent with the view that LYZ-81 is less toxic to normal cells than is OSW-1.
LYZ-81 Preferentially Eradicates LSCs Ex Vivo and In Vivo
To assess the capacity of LYZ-81 treatment ex vivo to reduce LSCs engraftment, we pre-treated AML-CD 34+ or umbilical cord (UBC)-CD 34+ cells with LYZ-81 and transplanted them into sublethally irradiated NOD/SCID mice ( Figure S3A ). Ex vivo pre-treatment of AML-CD 34+ cells with LYZ-81 significantly reduced the engrafted LSCs in mouse bone marrow ( Figure S3B ). Relative gene expression is presented as log(2 ÀDDCt ). The western blot is representative of 3 independent experiments with similar results. (C) The in vitro colony-forming ability of LSCs (n = 3, AML 1, 2, 3 specimens) with ORP4L knockdown. After infection with non-targeting shRNA (shNT) or shORP4L lentivirus for 48 h, the infected cells with GFP were sorted by flow cytometer and plated in Methocult GF and cultured for 14 days. Representative colony microscopy images of the specimens are shown. Mean ± SD values from an experiment performed in triplicate with each specimen are plotted. **p < 0.01, Student's t test. (D) Cell death analysis in LSCs (n = 10) with ORP4L knockdown. Cells were infected with shNT or shORP4L lentivirus for 120 h before analysis. Representative images of cell death analysis by fluorescence-activated cell sorting (FACS) are shown. The percentage of cell death from independent AML specimens are shown. **p < 0.01, Student's t test.
(E) Percentage of engraftment of leukemia cells (AML 2 specimen) in the bone marrow of NOD/SCID mice (n = 8 for shNT, and n = 6 for shORP4L). Representative images of FACS analysis from one of the mice are shown. The engraftment percentages of leukemia cells from each mouse are plotted. ***p < 0.001, Student's t test.
In contrast, engraftment of HSCs was not affected by LYZ-81 treatment ( Figure S3C ). The decreased engraftment of LYZ-81-treated LSCs was partly rescued by the overexpression of ORP4L before the treatment ( Figure S3D ), which is consistent with the view that LYZ-81 eliminates LSCs via targeting ORP4L.
To test the therapeutic potential of LYZ-81, we treated NOD/ SCID mice engrafted with AML-CD 34+ or UBC-CD 34+ cells with LYZ-81 for 7 weeks ( Figure 3A ). The engrafted leukemia cells and LSCs were determined before and after 1, 2, 4, 5, and 7 weeks of treatment by analyzing peripheral blood leukocytes. Notably, increased numbers of hCD45 + cells and LSCs were found in mice injected with PBS in a series of treatment time courses ( Figure S4A ), while remarkable reductions in hCD45 + cells and LSCs were evident after 4 and 5 weeks of LYZ-81 treatment. No detectable hCD45 + cells or LSCs were found in the peripheral blood of the animals after LYZ-81 treatment for 7 weeks ( Figure S4A ). LYZ-81 did not exert a significant reduction in hCD45 + cells or HSCs in mice engrafted with HSCs ( Figure S4B ). -4, -5, -6, -7, -8, -9, -11, -12, -13, and -14 specimens) treated with increasing concentrations of LYZ-81 are shown. Details of each AML specimen are shown in Table S1 . (F) The in vitro colony-forming ability of LSCs in the first and second replanting (n = 5, AML-1, -2, -5, -6, and -10 specimens) and HSCs (n = 4) as examined in the absence or presence of 5 nM LYZ-81. Data are means ± SDs of at least three independent experiments. **p < 0.01, ***p < 0.001, NS, not significant, Student's t test.
(G) H&E stained tissue sections of mice treated with LYZ-81 or OSW-1. The mice were sacrificed after drug treatments at 5.8 mg/kg/day, intraperitoneally (i.p.) for 7 weeks. Similar results were obtained for five mice in each group. Images from one representative mouse per group are shown. Scale bars, 100 mm.
After 7 weeks of therapy, we analyzed the bone marrow of the mice. The LYZ-81 treatment fully eliminated leukemia cells and LSCs from the bone marrow ( Figures 3B and 3C ). However, LYZ-81 did not reduce the engraftment of HSCs ( Figure 3D ). Staining of spleen and bone marrow sections with anti-hCD34 supported the notion that LYZ-81 can completely eradicate LSCs in vivo ( Figure 3E ). Furthermore, LYZ-81 therapy significantly delayed tumor-related death of the animals ( Figure 3F ). Thus, pharmacologic inhibition of ORP4L by LYZ-81 markedly and selectively eradicates LSCs both in vitro and in vivo.
ORP4L Facilitates PIP 2 Clearance in the PM Similar to Jurkat T cells, ORP4L interacts with Ga q/11 and PLCb3 upon stromal cell-derived factor 1a (SDF-1a) (a cytokine binding G protein-coupled receptor CXCR4 [Murdoch, 2000] ) stimulation in LSCs ( Figures S5A and S5B ). Knockdown of PLCb3 significantly reduced IP 3 production in LSCs ( Figure S5C ), indicating that the PLCb3 isoform plays a dominant role in IP 3 production in these cells. ORP4L depletion significantly reduced the spontaneous cytosolic [Ca 2+ ] c and mitochondrial [Ca 2+ ] m oscillations ( Figure S5D ) that are associated with the inactivation of pyruvate dehydrogenase (PDH; Figure S5E ), reduction of oxygen consumption rate (OCR), and ATP production ( Figure S5F ). Furthermore, ORP4L knockdown reduced AMP kinase (AMPK) activation and induced autophagy ( Figure S5G ). To strengthen the link between ORP4L, Ca 2+ signaling and mitochondrial metabolism, we used the mitochondrial calcium uniporter (MCU) agonist kaempferol (Montero et al., 2004) , which abolished the inactivation of PDH, the elevated autophagy, the reduced OCR, and the dampened ATP production upon ORP4L knockdown ( Figure S5H ). LSC death was rescued by the inhibitor of autophagy, 3-methyladenine ( Figure S5I ), indicating that ORP4L knockdown induced LSC death via an autophagic mechanism.
To identify the function of ORP4L in LSCs, we carried out the following experiments in the CD34 + CD38 À KG1-a cell line that meets the properties of stem cells (She et al., 2012) . ORP4L is highly expressed in CD34 + CD38 À KG1-a cells ( Figure S6A ), and its knockdown ( Figure S6B ) induced cell death ( Figure S6C ). Prompted by the functions of ORPs as lipid transporters and role of ORP4L with IP 3 production at the PM, we isolated PM from control and ORP4L-deficient CD34 + CD38 À KG1-a cells. Global lipidomics profiling revealed that phosphatidylinositols (PIs) were significantly enriched, whereas the products of PLC, DAGs, were reduced upon the loss of ORP4L ( Figure 4A ), indicating a function of ORP4L in the metabolism of PI at the PM. We therefore measured the kinetics of PIP 2 clearance in the PM after ligand stimulation. The PM PIP 2 levels declined steadily after SDF-1a stimulation of KG1-a cells, and ORP4L knockdown reduced (Figures 4B and 4D; Video S1) while ORP4L overexpression accelerated the clearance of PIP 2 ( Figures 4B and 4E ). Similar effects of ORP4L manipulations on PIP 2 clearance were observed in primary LSCs upon SDF-1a stimulation ( Figure 4C ).
ORP4L Binds and Extracts PIP 2 from the PM To investigate whether ORP4L regulates PIP 2 clearance at the PM by a direct interaction with PIP 2 , the three-dimensional (3D) structure of ORP4L-ORD was predicted through homology modeling and subjected to 100-ns molecular dynamics simulations with the head group of PIP 2 . According to root-mean- Figure S6E . After reaction, the PIP 2 remaining in the PM were analyzed. (K) Dot-blot to determine the ability of ORP4L and the indicated truncated ORP4L constructs to extract PIP 2 . square deviation (RMSD) curves, the pocket entrance (residues 520-540, 622-631, and 836-853) of apo-ORP4L expanded during 30-60 ns and then restored a closed conformation (Figure 5A ; Video S2). However, as for the ORP4L/PIP 2 complex, the pocket entrance expanded over time ( Figure 5B ; Video S3). In the privileged conformation, PIP 2 formed hydrogen bonds with specific hydrophilic residues of ORP4L (Arg537, Asn600, Ser650, Lys652, Gln848, Arg849, and Arg852) at the pocket entrance area ( Figure 5C ). Alignment of ORP4L/PIP 2 with apo-ORP4L revealed that the pocket entrance in ORP4L/PIP 2 expanded (magenta lines in Figure 5D ). Immunofluorescence staining showed the co-localization of ORP4L and PIP 2 in KG1-a and LSCs ( Figure S6D ). SPR assays further confirmed that the full-length ORP4L ( Figure 5E ) and its ORD ( Figure 5F ) but not its Pleckstrin homology (PH) domain ( Figure 5G ) bind PIP 2 . The ORD of ORP4L has higher affinity for PIP 2 than the PH domain of PLCb3 ( Figure 5H ), indicating a preference of PIP 2 for binding ORP4L.
Given the direct ORP4L/PIP 2 interaction, we postulated that ORP4L may extract PIP 2 from the PM. After incubating PMs with purified glutathione S-transferase (GST)-PLCb3 or GST-ORP4L proteins, the PMs were collected and the PIP 2 remaining in the membranes was analyzed to monitor the extraction capacity of the proteins ( Figure 5I ). PLCb3 was activated by guanosine triphosphate (GTP)gS ( Figure S6E ), as previously described (Hepler et al., 1993) . We found that PLCb3 (inactive or GTPgSbound active form) alone was unable to extract PIP 2 ( Figure 5J ). In contrast, incubation with ORP4L decreased the amount of PIP 2 in the PM fraction, with a concomitant increase in its amount bound to the ORP4L ( Figure 5K ), demonstrating the extraction of PIP 2 from the PM by ORP4L. Furthermore, the ORD but not the PH domain of ORP4L was crucial for its PIP 2 extraction capacity ( Figure 5K ).
ORP4L Presents PIP 2 to PLCb3 for Hydrolysis
We next reconstituted a cell-free system to study the hydrolysis of PIP 2 in the presence or absence of ORP4L and PLCb3. To exclude endogenous ORP4L, PMs were isolated from KG1-a cells with 90% knockdown of ORP4L. After the reaction, pellets containing the PM were analyzed for PIP 2 and DAG and the supernatants for IP 3 ( Figure 6A ). PLCb3 alone did not induce the loss of PIP 2 or the production of second messengers DAG and IP 3 . However, the combination of ORP4L and PLCb3 dramati- cally decreased the PIP 2 level and concomitantly increased the production of the second messengers. We next generated ORP4L mutants deficient in PIP 2 binding (replaced Arg537, Asn600, Ser650, Lys652, Gln848, Arg849, and Arg852 by Gly, ORP4LDPIP 2 ) and PLCb3 binding (ORP4LDPLCb3) (Zhong et al., 2016a) . These two ORP4L mutants abolished the effects of the protein on PIP 2 , DAG, and IP 3 ( Figure 6B ). In living cells, ORP4L knockdown reduced the clearance of PIP 2 ( Figures 6C and 6D , left) and decreased the second messengers ( Figures 6E and 6F , left) in both KG1-a and LSCs, while PLCb3 overexpression increased all of these parameters, these effects being abolished upon ORP4L knockdown ( Figures 6C and 6D , left; Figures 6E and 6F, left) . Our recent work showed that ORP4L is required for PLCb3 translocation from the nucleus to the PM. In ORP4L knockdown cells, wild-type ORP4L and ORP4LDPIP 2 rescued the PLCb3 translocation, indicating that abolishing PIP 2 binding by ORP4L did not affect the role of ORP4L in PLCb3 translocation. However, the ORP4LDPLCb3 mutant was unable do this ( Figure S6F ). Overexpression of wild-type ORP4L but not the mutants increased the PIP 2 clearance ( Figures 6C and 6D, right) and second messenger production ( Figures 6E and 6F, right) . Although the ORP4LDPIP 2 mutant retained the PLCb3 translocation ability, the defect of PIP 2 hydrolysis in ORP4LDPIP 2 overexpressing cells indicated the requirement of PIP 2 extraction and presentation for this catalysis. Of note, IP 3 was released after PLC catalysis in our cellfree system and in living cells. To address the dissociation of IP 3 from the binding pocket of ORP4L, 2-ns steered molecular dynamics (SMD) were performed on the ORP4L/IP 3 complex through 100-ns MD simulations. At the beginning, IP 3 was bound in the binding pocket of ORP4L at Arg 537, Lys 597, Asn 600, Ser 650, Ser 651, Lys 652, Arg 849, and Arg 852. During the 2-ns SMD simulations, the hydrogen bonds were broken, and IP 3 eventually escaped from the binding pocket. Pulling IP 3 outside the binding pocket of ORP4L was calculated to cost 17.85 ± 2.10 kcal/mol work ( Figure 6G ; Video S4).
LYZ-81 Blocks PIP 2 Hydrolysis by Targeting ORP4L
We further investigated the detail mechanism of LYZ-81 cytotoxicity. Microscale thermophoresis (MST) indicated that LYZ-81 competed with PIP 2 for binding to ORP4L ( Figure 7A ). In the cell-free reconstituted system, LYZ-81 inhibited the extraction of PIP 2 by ORP4L in a dose-dependent manner ( Figure 7B ) and decreased PM PIP 2 clearance and production of the second messengers ( Figures 7C and 7D ). Similar to ORP4L knockdown, LYZ-81 treatment increased in living LSCs the PM PIP 2 levels and reduced second messenger production; these effects were partly rescued by ORP4L overexpression ( Figure 7E ). Moreover, LYZ-81 treatment decreased the [Ca 2+ ] c and [Ca 2+ ] m oscillations ( Figure 7F ), increased phospho (p)-PDH and p-AMPK, and reduced OCR and ATP production in LSCs ( Figure 7G ), while ORP4L overexpression consistently reversed these effects. LYZ-81 treatment also induced the autophagic death of the LSCs (Figure 7H ). The full-length ORP4L but not ORP4LDPIP 2 rescued the cell death induced by LYZ-81 (Figure 7I) , indicating that blocking PIP 2 extraction and presentation by ORP4L is the key mechanism underlying LYZ-81 cytotoxicity. Furthermore, we isolated and analyzed the remaining human LSCs from animals grafted with AML-6 (see Figure 3B ). LYZ-81 treatment of the engrafted animals reduced the PDH activity and increased the p-AMPK levels and autophagy in these cells ( Figure 7J ), which is consistent with the view that LYZ-81 eradicates LSCs via an autophagic pathway also in vivo.
DISCUSSION
In this study, we found that ORP4L inhibition selectively eradicated LSCs in vitro and in vivo. ORP4L was found to be expressed selectively in LSCs, but not in normal HSCs, and to play an essential role in the survival of LSCs. The protein is required for PIP 2 extraction from the PM and its presentation for PLCb3 to complete PIP 2 hydrolysis, Ca 2+ release, and subsequent bioenergetics. Through this mechanism, ORP4L was found to maintain the oxidative phosphorylation and survival of LSCs. Meanwhile, we found that this process in LSCs may serve as a target for the development of pharmaceuticals for leukemia therapy.
Reprogramming of energy metabolism has been substantiated as an emerging hallmark and therapeutic target in leukemia (Hainaut and Plymoth, 2013; Hanahan and Weinberg, 2011) . However, its targeting in cancer cells is challenging, as the healthy cells depend on the same pathways for energy supply (Hainaut and Plymoth, 2013) . ORP4L is expressed in T-ALL cells and LSCs from AML patients but not in T cells or HSCs. We selected AML-LSCs as a target for the investigation of the therapeutic potential of ORP4L. ORP4L knockdown in the LSCs resulted in defective bioenergetics and autophagic death of the cells; the specific inhibitor of ORP4L, LYZ-81, showed similar effects. LYZ-81 was capable of selectively eradicating engrafted human LSCs from NOD/SCID recipient mice after ex vivo or in vivo treatments. We therefore consider ORP4L to be a potential target of pharmaceuticals for leukemia therapy.
In general, the processes regulating IP 3 generation are well mapped and are known to play fundamental roles in a variety of Ca 2+ -dependent cell signaling pathways. Our study offers the extended insight into PLC catalysis that a cofactor is required for PIP 2 extraction from the PM and its presentation for PLC. Our recent study (Zhong et al., 2016b) demonstrated that ORP4L interacts with PLCb3 in T-ALL cells. Here, ORP4L is found to be expressed selectively in LSCs but not in normal HSCs and to play a critical role in LSCs bioenergetics. It forms a complex with Ga q/11 and PLCb3 to control cytosolic and mitochondrial parallel Ca 2+ spike oscillations that sustain oxidative phosphorylation. We found that ORP4L extracts PIP 2 from the PM, while PLCb3 is unable to do this. In living KG1-a and LSCs, ORP4L knockdown resulted in the retention of PIP 2 in the PM, which could not be reversed by overexpressing PLCb3. Overexpression of wild-type ORP4L but not mutants deficient in PIP 2 or PLCb3 binding induced PIP 2 hydrolysis by PLCb3. These findings were supported by data from a cell-free reconstituted system. The results indicated that the PIP 2 extracted by ORP4L could be delivered to its cognate PLCb3 via a physical interaction of the two proteins.
Our MD simulations supported the notion that ORP4L accommodates PIP 2 within its ORD. In the cell-free system, ORP4L alone could extract PIP 2 from the PM, and the addition of PLCb3 allowed PIP 2 hydrolysis, the reaction product DAG remaining in the PM. We thus envision that in living cells, the PLC reaction does not involve complete extraction and accommodation of the PIP 2 fatty acyl chains within the ORP4L ORD. We hypothesize that the ORP4L interacts with the membrane-bound PIP 2 with the inositol-phosphate-binding cleft at the mouth of the ORD pocket, thereby pulling the PIP 2 partly out of the membrane for immediate hydrolysis by the PLCb3. The DAG produced would thus remain in the PM.
To conclude, our data demonstrate that LYZ-81 selectively eliminates LSCs in vitro and in vivo via the inhibition of ORP4L, suggesting this compound as a starting point of drug development for LSCs elimination in leukemia.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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EXPERIMENTAL MODELS AND SUBJECT DETAILS

Human specimens and cell line
This study was approved by the institutional ethics committee of Jinan University and was performed in accordance with the Declaration of Helsinki. Normal umbilical cord (UCB) blood and human AML bone marrow samples were obtained after obtaining written informed consent at Guangdong General Hospital, Guangzhou and Department of Hematology, Chang Zheng Hospital, ShangHai. The clinical information and the applications for which each sample was used are provided in Table S2 . The AML and normal UCB cells were isolated and processed as previously described (Guzman et al., 2001) . The samples were collected and subjected to Ficoll-Paque density gradient separation to isolate mononuclear cells, followed by CD34 + CD38cells isolation by using MACS enrichment kit (Milltenyi Biotec, Auburn, CA) according to the manufacturer's manual, within 12 h of collection. The purity of the enriched CD34 + CD38cells was monitored by staining the cells with FITC conjugated anti-Human CD38 antibody (1:100; Miltenyi Biotec Cat# 130-092-259) and PE conjugated anti-Human CD34 antibody (1:100; Miltenyi Biotec Cat# 130-081-002), and analyzed by flow cytometry. The samples were cryopreserved in freezing medium consisting of Cryostor CS10 (BioLife Solutions, Bothell, WA). Upon thawing, the cells were cultured in Serum-Free Medium (STEMCELL Technologies, Vancouver, BC, Canada) supplemented with 10 ng/mL rIL3 (PeproTech, Rocky Hill, NJ), 10 ng/mL rFlt3 (PeproTech, Rocky Hill, NJ), and 25 ng/mL rSCF (PeproTech, Rocky Hill, NJ) at 37 C in a humidified atmosphere containing 5% CO 2 . Leukemic stem-like CD34 + CD38 -KG1-a cells were isolated from KG1-a cells purchased from American Type Culture Collection by using MACS enrichment kit. This cell line was authenticated by Promega short-tandem repeat analysis and tested for mycoplasma contamination before experiments. Cells were cultured in IMDM supplemented with 10% FBS and 100 units/mL penicillin and 100 mg/mL streptomycin in a humidified atmosphere containing 5% CO 2 .
Validation of the stem cell status of the isolated LSCs
To characterize ORP4L in LSCs, we enriched CD34 + CD38 -LSCs with purity greater than 95% from AML patients, predominantly representing quiescent G 0 cells ( Figure S7A) . In vitro colony-forming unit (CFU) assays indicated that the isolated LSCs are able to produce colonies after at least four re-plating ( Figure S7B ). Serial transplantation of LSCs from three individual AML specimens (i.e., successful engraftment in bone marrow of NOD/SCID mice) was readily evident after the 1 st transplantation (Figures S7C  and S7D ). Injection of LSCs purified from the 1 st engrafted mice resulted in successful engraftment in the 2 nd recipients. The transplanted LSCs gave rise to CD34 + CD38 -, CD34and CD34 + CD38 + non-stem AML cells in the 1 st and 2 nd recipients, indicating the long-term engraftment and differentiation capacity of our purified LSCs. Moreover, immunofluorescence staining of bone marrow and spleen sections with anti-hCD34 showed infiltration of human AML cells in the transplant recipient mice ( Figure S7E ).
Animal studies NOD/SCID mice were obtained from Nanjing Biomedical Research Institute of Nanjing University and kept under pathogen-free conditions in the Laboratory Animal Center, Jinan University. All procedures were performed based on the UCLA Animal Research Committee-approved protocols. 4 week-old female mice were sublethally irradiated with 11 rad/g by a 137 Cs irradiator (Gammacell 3000 Elan, Best Theratronics, Kanata, ON, Canada) and used for transplantation within 24 h. For experiments in Figure 1E , AML-CD34 + cells were infected with shNT and shORP4L lentivirus for 48 h, the infected cells with GFP were sorted by flow cytometry; for experiments in Figure S3A , AML-CD34 + and UCB-CD34 + cells pre-incubated with 5 nM LYZ-81 for 4 h. NOD/SCID mice were injected with 1 3 10 7 treated cells via the tail vein in a final volume of 0.2 mL of PBS with 0.5% FBS. Engraftment was assessed 8 weeks after transplantation by Alexa Fluorâ 647 conjugated anti-human CD45 antibody (1:100; BioLegend Cat# 304026), FITC conjugated anti-Human CD38 antibody (1:100; Miltenyi Biotec Cat# 130-092-259) and PE conjugated anti-Human CD34 antibody (1:100; Miltenyi Biotec Cat# 130-081-002) staining of bone marrow cells. For in vivo therapy in Figures 3A and 1 3 10 7 AML-CD34 + cells were injected into irradiated NOD/SCID mice via the tail vein in a final volume of 0.2 mL of PBS with 0.5% FBS. After 6 weeks, the successful engraftment of human cells in peripheral blood was detected by flow cytometry, and then these mice were randomly assigned into 2 groups, and treated for 7 weeks with PBS or LYZ-81 (5.8 mg/ kg/d, i.v.) (Tamura et al., 1997) each day. Disease evolution and effect of drugs on the HSC-enriched and LSC-enriched compartments were determined after 7 weeks of treatment by flow cytometric analysis of human CD45 + CD34 + CD38cells in bone marrow. All of the animal experiments were repeated at least once.
For primary and serial xenogeneic transplantation of Figure S7C , 2 3 10 6 AML-CD34 + CD38cells from patients were injected into NOD/SCID mice via the tail vein in a final volume of 0.2 mL of PBS with 0.5% FBS. 6 weeks after transplantation, primary recipient mice were sacrificed, the engraftments were analyzed by staining of bone marrow cells. The bone marrow of primary recipient mice were also collected, purified by using human CD34 + CD38cells MACS enrichment kit, then 2 3 10 6 human CD34 + CD38cells were injected into irradiated secondary recipients via the tail vein. 6 weeks later, secondary recipient mice were sacrificed and the engraftment of human bone marrow cells was analyzed by anti-human CD45, anti-human CD34 and anti-human CD38 staining.
METHOD DETAILS
Reagents and antibodies
Fluo4-AM, Rhod 2-AM, Alexa Fluor-488 goat anti-mouse IgG, Alexa Fluor-543 goat anti-rabbit IgG, Alexa Fluor-647 donkey anti-goat IgG and TRIzol reagent were purchased from Invitrogen (Carlsbad, CA). Rabbit anti-ORP4L, 3-MA and PIP 2 were from Sigma-Aldrich (St. Louis, MO). SDF-1a was from R&D Systems (Minneapolis, MN). Compounds C was from Merck Millipore (Billerica, MA). Kaempferol was purchased from Selleckchem. Alexa Fluor 647-anti-Ki67, Alexa Fluor 647-anti-human CD45, PE-anti-human CD34 and FITC-anti-human CD38 were obtained from BioLegend (San Diego, CA). Anti-pan-cadherin was from Santa Cruz (Santa Cruz, CA). Anti-PIP 2 and BODIPYâ FL-PIP 2 were from echelon-inc. Anti-p-PDH was obtained from Novus (St. Louis, MO); anti-LC3, anti-p-AMPK, anti-PDH and anti-AMPK from Cell Signaling (Beverly, MA), and anti-actin from Proteintech Group (Chicago, IL).
Gene transfer
High-titer lentiviral stocks (above 10 9 TU/mL) carrying GFP-tag and shRNA-ORP4L, or ORP4L-cDNA were prepared by Shanghai GenePharma Co (Shanghai, China). The shRNA sequence can be found in Table S3 . For lentivirus infection, 1 3 10 6 cells were resuspended in 100 mL medium containing lentivirus (Multiplicity of infection, MOI = 100) and 5 mg/mL polybrene in 24-well culture plates. Infections were carried out for 6 h at 37 C, 5% CO 2 . After the end of infection, 400 mL medium was added. Knockdown or overexpression was verified by western blotting after 4 and 2 days' infection, respectively. For other gene transfers, cells were electroporated using Nucleofector TM Kits for Human CD34 + cells and 4D-Nucleofector TM System (Lonza, Basel, Switzerland) according to the manufacturer's instructions. Functionality of cDNA overexpression by plasmid transfection was similarly verified by western blotting. Primer sequences used for cDNA subcloning into vectors are provided in Table S3 .
Quantitative real-time PCR
Total RNA was isolated with TRIzol reagent (Invitrogen) according to the manufacturer's instructions. RNA samples were reverse transcribed using random hexamer primers in the presence of RNase inhibitor (Takara Bio, Shiga, Japan). qRT-PCR was performed with SYBR Premex EX Taq (Takara Bio) using the 7300 Sequence Detection System (Applied Biosystems, Foster City, CA). The data was filtered as follows: if the cycle threshold (C t ) score for sample was ''Undetermined,'' or if the C t score was > 35, the score was set to 40 (McCall et al., 2014) . A relative quantification analysis was performed using the DDCt method, with actin as endogenous reference. Relative gene expression is presented as log (2 -DDCt ). Primer sequences used are provided in Table S3 .
PM preparations PM was prepared by using Plasma Membrane Protein Isolation and Cell Fractionation Kit (Invent Biotechnologies, Inc.) according to the manufacturer's instructions.
Lipidomics profiling by UPLC-HRMS
Freeze-dried cellular membrane samples were spiked with lipid internal standard solution (in methanol) containing lyso-phosphatidylcholine (LPC) 19:0, phosphatidylcholine (PC) (19:0/19:0), phosphatidylethanolamine (PE) (17:0/17:0), sphingomyelin (SM) (d18:1/ 12:0), triacylglycerol (TAG) (15:0/15:0/15:0), ceramide (Cer) (d18:1/17:0), free fatty acid (FFA) 16:0-d3 and FFA 18:0-d3. The mixture was vortexed for 1 min followed by addition of 1 mL of methyl tert-butyl ether and 15 min shaking. Then 250 mL of water was added for biphasic formation. The up-layer organic phase was collected and freeze-dried. The lipid residue was dissolved prior to analysis.
Cellular PM lipidomics profiling was performed in a Waters UPLC system coupled with a Q Exactive HF mass spectrometry (Thermo Fisher Scientific, Rockford, IL, U.S.A.) Chromatographic separation of lipids was achieved in a BEH C8 column (2.1 mm 3 100 mm, 1.7 mm, Waters, Milford, MA, U.S.A.). The elution solvents consisted of A (ACN: H2O = 60:40, v/v) and B (IPA: ACN = 90:10, v/v), both contained 10 mM ammonium acetate. The elution composition started at 32% B for the initial 1.5 min followed by a linear increase to 85% B during the next 14 min, and then rapidly increased to 97% B at 15.6 min. After was mixed with ORP4L at a 1:1 ratio followed by incubation for 30 min at room temperature in the dark. Unbound dye was removed by gel filtration on Sephadex G25 (GE Healthcare). The purity was monitored by measuring the ratio of protein to dye (spectroscopically by measuring absorption at 280 nm for the protein and 650 nm for the dye) after the clean-up procedure.
The concentrations of compounds were remained at 1 mM in a binding buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.05% Tween-20). After 30 min incubation, the samples were loaded into microscale thermophoresis (MST)-grade glass capillaries. The intensities of the LED and laser were set at 40%. The MST analyses were performed using a Monolith NT.115 and the fitting curve was obtained using NTA analysis 1.4.23 via Hill fitting, and the KD is the numeric equivalent of the concentration of LYZ-81 or PIP 2 when the response is half of the plateau response (Rmax).
IP 3 and DAG measurement IP 3 was measured using the HitHunter IP 3 Fluorescence Polarization Assay Kits (DiscoverRx Tech, Fremont, CA, USA) according to the manufacturer's instructions. For the DAG measurement, the PMs were disrupted by ultrasonication, after centrifugation, the suspension was used for analysis by using (DAG/DG) ELISA Kit (J&L Biological, ShangHai, China) according to the manufacturer's instructions.
Surface plasmon resonance assay SPR experiments were carried out using a ProteOn XPR36 SPR instrument (BioRad Hercules, CA). Immobilization of proteins was performed using amine coupling to a General Layer Medium (GLM) (medium density) biosensor chip (BioRad). Standard amine coupling was used to immobilize proteins (20 nM in 10 mM sodium acetate buffer, pH 4.5) to the EDAC/Sulfo-NHS activated surface of a GLH biosensor chip (BioRad) at a density of 200-600 resonance units (RU) according to the manufacturer's instructions. After the injection of proteins, the surface was blocked with 1 M ethanolamine. The final immobilization level for proteins was approximately 12,000 RU. Compound was prepared in phosphate buffered saline, pH 7.4, containing 0.005% Tween-20 and injected at 100 mL/min for 250 s at concentrations of 10-0.625 mM (1:2 dilutions). Following compound injection, the chip surface was regenerated with 40 s pulses of running buffer. The compound concentration data collected were reference-subtracted using Biacore Evaluation software. Titrations were reference-subtracted using ProtedOn ManagerTM 2.0. Each titration was globally analyzed using the 1:1 Langmuir binding model to obtain the kinetic rate constants (k on and k off ). The equilibrium dissociation constant (KD) was calculated from the rate constants. Global kinetic rate constants (k a and k d ) were derived for each reaction, and the equilibrium dissociation constant, KD, was calculated using the equation KD = k d / k a .
Molecular docking
A homology model of ORP4L was generated based on a crystal structure of Osh3 ORD from Saccharomyces cerevisiae (PDB entry code: 4IC4) using Molecular Operating Environment (http://www.chemcomp.com) software. The sequences of these two models at the binding pocket area are highly conserved. Hydrogen atoms were added to the protein using the MOE modeling suite before carrying out the docking studies. Minimizing contacts for hydrogen, the structures were subjected to an Amber99 energy minimization protocol. The structure of LYZ-81 was energy-minimized, the atomic partial charges were calculated with the MMFF94s force field, and all possible ionization states were generated at pH 7.0. LYZ-81 was docked into the homology model using MOE; the binding site was modeled based on previous information on the sterol binding site (Im et al., 2005) . The default Triangle Matcher was used as the placement method followed by force field refinement, and London DG scoring was used for the docking. The top-ranked conformation of the compound was selected for the ligand-receptor binding mode analysis (Clark and Labute, 2007) .
MD simulation
The coordinates of PIP 2 were obtained from the crystal structure of Osh3 ORD in complex with PI(4)P from Saccharomyces cerevisiae (PDB code: 4INQ). ORP4L/PIP 2 complex was generated by superposing ORP4L and 4INQ. GPU-based (Gö tz et al., 2012; Salomon-Ferrer et al., 2013) MD simulations were performed on the ORP4L/PIP 2 complex and apo-ORP4L using the PMEMD module from AMBER 12 (D.A. Case et al., 2012) .
The partial atomic charges of IP 3 were calculated through the Gaussian 09 (Frisch et al., 2009 ) program by using the Hartree-Fock method with the 6-31G(d) basis set. The Antechamber program was then used for fitting the restricted electrostatic potential (RESP) and assigning the GAFF force field parameters (Mukherjee et al., 2011) . For the protein receptor ORP4L, the AMBER ff12SB force field was used (Cornell et al., 1995; Hornak et al., 2006) . The ligand-receptor complex was neutralized by adding sodium/chlorine counter ions, and solvated in an octahedral box of TIP3P (Wang et al., 2006) water molecules with solvent layers 10 Å between the box edges and solute surface. The SHAKE (Miyamoto and Kollman, 1992; Ryckaert et al., 1977) algorithm was used to restrict all covalent bonds involving hydrogen atoms with a time step of 2 femtoseconds (fs). The Particle mesh Ewald (PME) method (Darden et al., 1993) was performed to treat long-range electrostatic interactions.
Three steps of minimization were performed before the heating step. All atoms were restrained with 50 kcal/(mol,Å 2), whereas the solvent molecules were not restrained. This step included 2,000 cycles of steepest descent minimization and 2,000 cycles of conjugated gradient minimization. Second, all heavy atoms were restrained with 10 kcal/(mol,Å 2) during the minimization steps, which included 2,500 cycles of steepest descent minimization and 2,500 cycles of conjugated gradient minimization. The third step included 5,000 cycles of steepest descent minimization and 5,000 cycles of conjugated gradient minimization without restraint.
After the energy minimizations, the whole system was heated from 0 to 300 K in 50 picoseconds (ps) using Langevin dynamics at a constant volume and then equilibrated for 400 ps at a constant pressure of 1 atm. A weak constraint of 10 kcal/ (mol,Å 2) was used to restrain all heavy atoms in the receptor-ligand complexes during the heating steps. Finally, periodic boundary dynamic simulations were conducted on the whole system with an NPT (constant composition, pressure, and temperature) ensemble at a constant pressure of 1 atm and 300 K in the production step. Each system was simulated for 100 ns. The coordinates of each system were saved every 4 ps. The root-mean-square deviations (RMSDs) of ORP4L, pocket loop (residues 520-540), and IP 3 were calculated. Clustering was applied to detect populated conformations with pairwise RMSD of 1.5 Å (Ca only) as the cutoff.
Binding energy calculation
The binding energies (DG binding ) of IP 3 to ORP4L were calculated using MM/PBSA method from AmberTools suite in Equation (1):
where Gepx is receptor-ligand complex energy, Gepx is unbound receptor energy, and Glig is ligand energy. MM-PBSA (Molecular Mechanics-Possion-Boltzmann/Surface Area) calculates the binding free energy considering the desolvation of the ligand and the unbound protein on the basis of a thermodynamic cycle. Equation (1) is also approximately calculated the follows:
where DEMM is the molecular mechanical energy obtained from the electrostatic (DE ele ) and the van der Waals (DE ndw ) interactions within the system, is the solute entropic contribution at temperature T (kelvin) and the solvation free energy (DG sol ) represents the electrostatic and nonpolar free energy of solvation. DG sol is calculated inEquation (4):
where D eel sol is the polar contribution to solvation, and DG nonpoular sol is the nonpolar solvation term. The former component was calculated using the PB calculation, whereas the latter term is determined using Equation (5):
where SASA is the solvent-accessible surface area (Å 2) and g and b represent experimental solvation parameters.
Steered MD simulation
Three different snapshots of ORP4L/IP 3 were taken from the MD simulation trajectories after the system reached stable. They were subjected for 2 ns SMD simulations where the restraint is time-dependent as in:
V rest ðtÞ = k½x À x 0 ðtÞ 2 Where ðxÞ is the distance of the specified atoms. SMD simulations were performed under the NVT ensemble. The maximal pulling distance was set to 10 Å between IP 3 and the binding pocket of ORP4L (Asn 600). In order to avoid any distortions of the protein due to pulling, the backbone of ORP4L was restrained with a force constant of 50 kcal/(mol,Å 2 ). SMD simulations were repeated 3 times with different staring ORP4L/IP 3 complexes. By integrating the force over distance, a generalized work can be computed.
Co-immunoprecipitation CD34 + CD38 -KG1-a cells were washed twice with ice-cold PBS and incubated on ice for 30 min with 1 mL lysis buffer (50 mM Tris-Cl, 150 mM NaCl, 0.5 mM MgCl 2 , 10% glycerol, and 0.5% Triton X-100, pH 8.0) supplemented with Protease Inhibitor Cocktail (Roche Group). Cell lysates were centrifuged for 10 min at 12,000 x g. The supernatant was preabsorbed for 1 h at 4 C with 50 mL of Protein G agarose (Invitrogen). The recovered supernatant was incubated overnight with ORP4L (3 mg; Sigma-Aldrich Cat#HPA021514) antibody at 4 C. 50 mL Protein G agarose was added to the lysate-antibody mixture and incubated at 4 C on a roller for 2 h. Agarose beads were washed four times with lysis buffer and boiled in 30 mL of SDS-PAGE loading buffer. Samples were resolved on 10% SDS-polyacrylamide gels and subjected to western blot analysis.
Immunofluorescence microscopy
For immunofluorescence staining of cells, cells seeded onto coverslips were stimulated with or without 500 ng/mL SDF-1a for 3 min and fixed with 4% paraformaldehyde for 30 min at room temperature, followed by permeabilization with 0.1% Triton X-100 for 5 min, (Thr172) (1:1000; Cell Signaling Technology Cat#2535), anti-AMPK (1:1000; Cell Signaling Technology Cat# 2603), anti-LC3B (1:1000; Cell Signaling Technology Cat#2775). The detection was carried out by enhanced chemiluminescence (Thermo Fisher Scientific).
QUANTIFICATION AND STATISTICAL ANALYSIS
All data is presented as mean ± SD. The value of n is mentioned in the figure legends and always stands for separate biological replicates. All in vitro experiments were repeated at least twice, and in vivo experiments were repeated at least once. All comparisons between groups were made by unpaired two-tailed Student's t test. Differences with * p < 0.05, **p < 0.01, and ***p < 0.001 were considered statistically significant. n.s., not significant.
